Q1 FY2026 saw modest sales growth and a decline in ordinary profit due to fewer closed deals, but higher M&A sales per transaction and strong leading indicators support a positive outlook. Extraordinary gains from the fund business and robust new mandates position the company for continued growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.